title: Targeted molecular therapy in peripheral T-cell lymphomas.
abstract: Peripheral T-cell lymphomas (PTCLs) are rare neoplasms constituting a heterogeneous group of diseases. At present, available chemotherapy regimens that have improved outcomes in B-cell lymphomas appear to be less efficacious in the context of PTCLs and, thus, alternative strategies are warranted. In the last few years, based on the recent, deeper understanding of PTCL biology, several molecules and/or pathways have been proposed for targeted therapy in this setting, including surface antigens, tyrosine kinases, the NF-κB pathway, folate metabolism, histone modification and others. Of particular interest, histone deacetylase and proteasome inhibitors, as well as novel chemotherapeutic agents such as pralatrexate, have already demonstrated efficacy in PTCL therapy. In addition, a strong biological rationale and early clinical evidence supports the future study of tyrosine kinase inhibitors in this setting. In this article, the authors review the available literature on targeted therapy in PTCLs and also, based on their own experience, discuss potential opportunities in this intriguing area.
authors.affiliation: Department of Haematology, St George Hospital, Sydney, Australia.
authors.forename: Fernando
authors.initials: F
authors.lastname: Roncolato
authors.forename: Anna
authors.initials: A
authors.lastname: Gazzola
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Stefano A
authors.initials: SA
authors.lastname: Pileri
authors.forename: Pier Paolo
authors.initials: PP
authors.lastname: Piccaluga
mesh_terms: D005492:Folic Acid / Q000737:chemistry / Q000378:metabolism; D006655:Histone Deacetylases / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000628:therapy*; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000628:therapy; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000037:antagonists & inhibitors / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D016328:NF-kappa B; D011956:Receptors, Cell Surface; D005492:Folic Acid; D020796:Receptor, Platelet-Derived Growth Factor alpha; D058570:TOR Serine-Threonine Kinases; D006655:Histone Deacetylases